Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Replimune's Tudriqev (RP1) wins FDA accelerated approval for advanced melanoma post-PD-1 therapy failure
Oncolytic virus, cancer, melanoma, combination therapy, PD-1, immunotherapy - Read more

TransThera Sciences' Yochanra (tinengotinib) wins China conditional approval for FGFR inhibitor-resistant cholangiocarcinoma after Ph2 success
Small molecule, cancer, kinase inhibitor, cholangiocarcinoma, FGFR2, drug resistance - Read more

Odyssey Therapeutics, Evotec partner on AI-driven drug discovery for autoimmune and inflammatory diseases
Research collaboration, AI/ML, autoimmune, small molecule, drug discovery, milestone payments - Read more

Rinn Pharma & Biopharma joins NordicPharmaTrain network to expand European pharmaceutical research collaboration
Research collaboration, pharmaceutical manufacturing, drug discovery, training & education - Read more

Harrow acquires TYRVAYA nasal spray for dry eye from Viatris, $30M upfront, up to $100M total
Acquisition, ophthalmology, small molecule, milestone payments, commercialization - Read more

Mediar Therapeutics, Ono Pharmaceutical collaborate on novel fibro-inflammatory disease treatments with exclusive licensing option
Research collaboration, fibrosis, autoimmune, antibody, licensing deal - Read more

From genomics to medical imaging to research, innovation needs the right data at the right time.

One global data fabric. Seamless collaboration. Access your data anywhere across on-premises, cloud, and edge.

Qumulo’s Life Sciences solution is enabling cutting-edge research in medicine and pharma. Explore the solution today.

Merck KGaA raises 2026 sales outlook to €21.8B ($25.2B), boosted by rare disease pillar from SpringWorks Therapeutics acquisition
Small molecule, rare disease, financial, major transaction - Read more

Latigo Biotherapeutics raises $345.6M IPO to advance non-opioid pain drug pipeline
Pain, small molecule, neurological, non-opioid, clinical-stage - Read more

Vedanta Biosciences raises $60M, advancing Phase III microbiome therapy for recurrent CDI
Microbiome therapy, infectious disease, live biotherapeutic, clinical-stage - Read more

Opal Therapeutics receives $1.25M NSF investment to scale organoid platform for women's health
Organoid platform, women's health, endometriosis, preclinical, biomarker discovery - Read more

Tarsus Pharmaceuticals acquires Alkeus Pharmaceuticals for up to $800M to develop Stargardt disease treatment
Small molecule, rare disease, major transaction, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Vistagen's (fasedienol) pheromone nasal spray fails to beat placebo in Ph2 social anxiety disorder study
Small molecule, neurological, nasal spray, social anxiety disorder, pherine - Read more

BioVie reports murky Ph2 results for (bezisterim) in Parkinson's disease, primary endpoint data withheld
Small molecule, neurological, Parkinson's disease, anti-inflammatory, blood-brain barrier - Read more

BioMarin Pharmaceutical scraps $270M BMN 401 program after phase 3 miss in ENPP1 deficiency
Enzyme replacement therapy, rare disease, strategic, major transaction - Read more

PacBio CEO Christian Henry steps down; COO Mark Van Oene named president and CEO amid widening Q2 losses
DNA sequencing, genomics, leadership change, financial, cost reduction - Read more

Fresenius Kabi recalls mislabeled morphine lot over dilaudid mix-up risking fatal overdose
Small molecule, pain management, operational, safety - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here